Optical Microscopy Imaging Contributes to Precision Oncology

被引:0
|
作者
Yang Bin [1 ]
Yue Shuhua [1 ]
Wang Pu [1 ]
机构
[1] Beihang Univ, Beijing Adv Innovat Ctr Biomed Engn, Sch Biol Sci & Med Engn, Beijing 100083, Peoples R China
来源
CHINESE JOURNAL OF LASERS-ZHONGGUO JIGUANG | 2024年 / 51卷 / 09期
关键词
precision oncology; next-generation sequencing; phenotypic functional assays; optical microscopy imaging; coherent Raman scattering; mid-infrared photothermal imaging; PROSTATE-CANCER; SOMATIC MUTATIONS; GASTRIC-CANCER; GENE FUSIONS; CYTOGENETIC RESPONSES; ORGANOID CULTURES; DRUG RESPONSE; LIVE CELLS; HIGH-RISK; RAMAN;
D O I
10.3788/CJL240447
中图分类号
O43 [光学];
学科分类号
070207 ; 0803 ;
摘要
Significance Precision oncology is imperative for accommodating the distinct journey of each cancer patient, which is determined by the unique genetic, molecular, and cellular profiles of individual tumors. This shift from a general treatment model to a personalized approach is driven by the recognition that each patient with cancer presents a distinct set of challenges that must be addressed to achieve optimal therapeutic outcomes and prognostic accuracy. The conventional methods of cancer treatment, which typically involve generalized therapies, are deficient owing to the heterogeneity of tumors and the dynamic nature of cancer progression. The complexity of tumor biology is a multifaceted challenge that is governed by the intricate relationship among genetic mutations, epigenetic alterations, and the tumor microenvironment. Tumors are not static-they evolve through a series of genetic and epigenetic changes that enables them to evade the host's immune system and resist the effects of various treatments. The tumor microenvironment, which comprises a diverse array of cell types, extracellular matrix components, and signaling molecules, significantly affect tumor growth, metastasis, and response to therapy. This renders it difficult to develop comprehensive treatment plans that can effectively target the specific characteristics of each tumor. Optical microscopy imaging technologies have been adopted widely in precision oncology as they can address the challenges posed by the complexity of tumor biology. These technologies allow one to visualize and analyze tumor tissues and cells with high resolution, thus enabling quantitative and spatially localized analysis of genomic, proteomic, and metabolomic information. This level of detail is critical for identifying patient-specific molecular characteristics and biochemical abnormalities for developing targeted treatment strategies. The significance of optical microscopy imaging in precision oncology is manifold. First, it bridges the difference between the genomic and phenotypic aspects of cancer, thus allowing for a more nuanced understanding of tumor behavior and response to therapy. Second, it enables the identification of biomarkers that can predict treatment response, thus providing guidance in selecting the most appropriate treatments for individual patients. Third, the non-invasive nature of these imaging techniques allows for the repeated monitoring of tumor progression and response to treatment, thereby facilitating real-time adjustments to treatment strategies as necessary. The potential of optical microscopy imaging to transform cancer treatment is substantial. By providing detailed, patient-specific information, these imaging techniques can facilitate the development of more effective and less-toxic treatment regimens. This personalized approach can improve patient outcomes by increasing the efficacy of therapies and reducing the incidence of adverse effects. Furthermore, the ability to monitor treatment response in real time can facilitate more informed clinical decision-making, thus potentially improving the overall survival rates and quality of life of patients with cancer. In conclusion, the integration of optical microscopy imaging into precision oncology is a significant advancement in cancer treatment. Optical microscopy imaging technologies are effective for understanding the complex biology of tumors and for guiding the development of personalized treatment strategies. As research in this field continues to progress, the potential for optical microscopy imaging to revolutionize cancer diagnosis and treatment will be immense, thus affording more targeted therapies and better patient outcomes in the future. The continued evolution of these technologies is crucial for bridging the disparity between genomic research and clinical practice, thus ultimately resulting in more effective and personalized cancer treatments. Progress Optical microscopy imaging techniques have progressed significantly in the field of precision oncology and can provide a comprehensive view of tumor characteristics. Auto-fluorescence ( AF) imaging has been utilized to monitor metabolic activities within tumors and offers label-free insights into drug responses and cellular metabolism (Fig. 5). Second harmonic generation (SHG) imaging has been pivotal for analyzing the extracellular matrix (ECM), particularly collagen fiber organization, which is crucial for understanding tumor invasion and metastasis (Fig. 7). Coherent Raman scattering (CRS), in particular stimulated Raman scattering (SRS), has emerged as an effective tool for imaging tumor metabolites without requiring labels. SRS has been instrumental in revealing metabolic heterogeneity, which is vital for identifying therapeutic targets and understanding cancer-cell metabolism (Fig. 8). Mid-infrared photothermal (MIP) imaging has demonstrated its potential in assessing drug pharmacokinetics and pharmacodynamics by imaging the distribution of drugs within cells and tissues at a deep cellular level (Fig. 9). Furthermore, multiplex immunofluorescence (mIF) and fluorescence in situ hybridization (FISH) have been employed for immunophenotyping (Fig. 4) and genetic analysis (Fig. 6), respectively, to characterize the immune microenvironment and detect gene amplifications. These techniques, as summarized in Table 1, collectively contribute to the increasing number of tools available for the characterization of tumors and the optimization of targeted therapies, thus ultimately improving patient outcomes in cancer treatment. Conclusions and Prospects Optical microscopy imaging is becoming essential in precision oncology as it allows one to understand the relationship between tumor genetics and phenotypes. As the field progresses, the integration of these imaging techniques into clinical settings will become more evident, which will significantly improve cancer diagnostics and treatment. Future studies shall be conducted to render this technology more accessible by reducing equipment costs and enhancing imaging methodologies, thereby solidifying its key role in precision oncology.
引用
收藏
页数:19
相关论文
共 138 条
  • [1] Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1
    Agrawal, Nishant
    Frederick, Mitchell J.
    Pickering, Curtis R.
    Bettegowda, Chetan
    Chang, Kyle
    Li, Ryan J.
    Fakhry, Carole
    Xie, Tong-Xin
    Zhang, Jiexin
    Wang, Jing
    Zhang, Nianxiang
    El-Naggar, Adel K.
    Jasser, Samar A.
    Weinstein, John N.
    Trevino, Lisa
    Drummond, Jennifer A.
    Muzny, Donna M.
    Wu, Yuanqing
    Wood, Laura D.
    Hruban, Ralph H.
    Westra, William H.
    Koch, Wayne M.
    Califano, Joseph A.
    Gibbs, Richard A.
    Sidransky, David
    Vogelstein, Bert
    Velculescu, Victor E.
    Papadopoulos, Nickolas
    Wheeler, David A.
    Kinzler, Kenneth W.
    Myers, Jeffrey N.
    [J]. SCIENCE, 2011, 333 (6046) : 1154 - 1157
  • [2] YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition
    Ajani, Jaffer A.
    Xu, Yan
    Huo, Longfei
    Wang, Ruiping
    Li, Yuan
    Wang, Ying
    Pizzi, Melissa Pool
    Scott, Ailing
    Harada, Kazuto
    Ma, Lang
    Yao, Xiaodan
    Jin, Jiankang
    Zhao, Wei
    Dong, Xiaochuan
    Badgwell, Brian D.
    Shanbhag, Namita
    Tatlonghari, Ghia
    Estrella, Jeannelyn Santiano
    Roy-Chowdhuri, Sinchita
    Kobayashi, Makoto
    Vykoukal, Jody V.
    Hanash, Samir M.
    Calin, George Adrian
    Peng, Guang
    Lee, Ju-Seog
    Johnson, Randy L.
    Wang, Zhenning
    Wang, Linghua
    Song, Shumei
    [J]. GUT, 2021, 70 (01) : 55 - +
  • [3] Transcription-mediated gene fusion in the human genome
    Akiva, P
    Toporik, A
    Edelheit, S
    Peretz, Y
    Diber, A
    Shemesh, R
    Novik, A
    Sorek, R
    [J]. GENOME RESEARCH, 2006, 16 (01) : 30 - 36
  • [4] Sequence analysis of mutations and translocations across breast cancer subtypes
    Banerji, Shantanu
    Cibulskis, Kristian
    Rangel-Escareno, Claudia
    Brown, Kristin K.
    Carter, Scott L.
    Frederick, Abbie M.
    Lawrence, Michael S.
    Sivachenko, Andrey Y.
    Sougnez, Carrie
    Zou, Lihua
    Cortes, Maria L.
    Fernandez-Lopez, Juan C.
    Peng, Shouyong
    Ardlie, Kristin G.
    Auclair, Daniel
    Bautista-Pina, Veronica
    Duke, Fujiko
    Francis, Joshua
    Jung, Joonil
    Maffuz-Aziz, Antonio
    Onofrio, Robert C.
    Parkin, Melissa
    Pho, Nam H.
    Quintanar-Jurado, Valeria
    Ramos, Alex H.
    Rebollar-Vega, Rosa
    Rodriguez-Cuevas, Sergio
    Romero-Cordoba, Sandra L.
    Schumacher, Steven E.
    Stransky, Nicolas
    Thompson, Kristin M.
    Uribe-Figueroa, Laura
    Baselga, Jose
    Beroukhim, Rameen
    Polyak, Kornelia
    Sgroi, Dennis C.
    Richardson, Andrea L.
    Jimenez-Sanchez, Gerardo
    Lander, Eric S.
    Gabriel, Stacey B.
    Garraway, Levi A.
    Golub, Todd R.
    Melendez-Zajgla, Jorge
    Toker, Alex
    Getz, Gad
    Hidalgo-Miranda, Alfredo
    Meyerson, Matthew
    [J]. NATURE, 2012, 486 (7403) : 405 - 409
  • [5] Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
    Barbieri, Christopher E.
    Baca, Sylvan C.
    Lawrence, Michael S.
    Demichelis, Francesca
    Blattner, Mirjam
    Theurillat, Jean-Philippe
    White, Thomas A.
    Stojanov, Petar
    Van Allen, Eliezer
    Stransky, Nicolas
    Nickerson, Elizabeth
    Chae, Sung-Suk
    Boysen, Gunther
    Auclair, Daniel
    Onofrio, Robert C.
    Park, Kyung
    Kitabayashi, Naoki
    MacDonald, Theresa Y.
    Sheikh, Karen
    Vuong, Terry
    Guiducci, Candace
    Cibulskis, Kristian
    Sivachenko, Andrey
    Carter, Scott L.
    Saksena, Gordon
    Voet, Douglas
    Hussain, Wasay M.
    Ramos, Alex H.
    Winckler, Wendy
    Redman, Michelle C.
    Ardlie, Kristin
    Tewari, Ashutosh K.
    Mosquera, Juan Miguel
    Rupp, Niels
    Wild, Peter J.
    Moch, Holger
    Morrissey, Colm
    Nelson, Peter S.
    Kantoff, Philip W.
    Gabriel, Stacey B.
    Golub, Todd R.
    Meyerson, Matthew
    Lander, Eric S.
    Getz, Gad
    Rubin, Mark A.
    Garraway, Levi A.
    [J]. NATURE GENETICS, 2012, 44 (06) : 685 - U107
  • [6] Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion
    Bass, Adam J.
    Lawrence, Michael S.
    Brace, Lear E.
    Ramos, Alex H.
    Drier, Yotam
    Cibulskis, Kristian
    Sougnez, Carrie
    Voet, Douglas
    Saksena, Gordon
    Sivachenko, Andrey
    Jing, Rui
    Parkin, Melissa
    Pugh, Trevor
    Verhaak, Roel G.
    Stransky, Nicolas
    Boutin, Adam T.
    Barretina, Jordi
    Solit, David B.
    Vakiani, Evi
    Shao, Wenlin
    Mishina, Yuji
    Warmuth, Markus
    Jimenez, Jose
    Chiang, Derek Y.
    Signoretti, Sabina
    Kaelin, William G., Jr.
    Spardy, Nicole
    Hahn, William C.
    Hoshida, Yujin
    Ogino, Shuji
    DePinho, Ronald A.
    Chin, Lynda
    Garraway, Levi A.
    Fuchs, Charles S.
    Baselga, Jose
    Tabernero, Josep
    Gabriel, Stacey
    Lander, Eric S.
    Getz, Gad
    Meyerson, Matthew
    [J]. NATURE GENETICS, 2011, 43 (10) : 964 - U67
  • [7] Real-time image guidance for brain tumor surgery through stimulated Raman scattering microscopy
    Bentley, Jessica Nicole
    Ji, Minbiao
    Xie, Xiaoliang Sunney
    Orringer, Daniel A.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (04) : 359 - 361
  • [8] Melanoma genome sequencing reveals frequent PREX2 mutations
    Berger, Michael F.
    Hodis, Eran
    Heffernan, Timothy P.
    Deribe, Yonathan Lissanu
    Lawrence, Michael S.
    Protopopov, Alexei
    Ivanova, Elena
    Watson, Ian R.
    Nickerson, Elizabeth
    Ghosh, Papia
    Zhang, Hailei
    Zeid, Rhamy
    Ren, Xiaojia
    Cibulskis, Kristian
    Sivachenko, Andrey Y.
    Wagle, Nikhil
    Sucker, Antje
    Sougnez, Carrie
    Onofrio, Robert
    Ambrogio, Lauren
    Auclair, Daniel
    Fennell, Timothy
    Carter, Scott L.
    Drier, Yotam
    Stojanov, Petar
    Singer, Meredith A.
    Voet, Douglas
    Jing, Rui
    Saksena, Gordon
    Barretina, Jordi
    Ramos, Alex H.
    Pugh, Trevor J.
    Stransky, Nicolas
    Parkin, Melissa
    Winckler, Wendy
    Mahan, Scott
    Ardlie, Kristin
    Baldwin, Jennifer
    Wargo, Jennifer
    Schadendorf, Dirk
    Meyerson, Matthew
    Gabriel, Stacey B.
    Golub, Todd R.
    Wagner, Stephan N.
    Lander, Eric S.
    Getz, Gad
    Chin, Lynda
    Garraway, Levi A.
    [J]. NATURE, 2012, 485 (7399) : 502 - 506
  • [9] Integrative analysis of the melanoma transcriptome
    Berger, Michael F.
    Levin, Joshua Z.
    Vijayendran, Krishna
    Sivachenko, Andrey
    Adiconis, Xian
    Maguire, Jared
    Johnson, Laura A.
    Robinson, James
    Verhaak, Roel G.
    Sougnez, Carrie
    Onofrio, Robert C.
    Ziaugra, Liuda
    Cibulskis, Kristian
    Laine, Elisabeth
    Barretina, Jordi
    Winckler, Wendy
    Fisher, David E.
    Getz, Gad
    Meyerson, Matthew
    Jaffe, David B.
    Gabriel, Stacey B.
    Lander, Eric S.
    Dummer, Reinhard
    Gnirke, Andreas
    Nusbaum, Chad
    Garraway, Levi A.
    [J]. GENOME RESEARCH, 2010, 20 (04) : 413 - 427
  • [10] Collagen organization of renal cell carcinoma differs between low and high grade tumors
    Best, Sara L.
    Liu, Yuming
    Keikhosravi, Adib
    Drifka, Cole R.
    Woo, Kaitlin M.
    Mehta, Guneet S.
    Altwegg, Marie
    Thimm, Terra N.
    Houlihan, Matthew
    Bredfeldt, Jeremy S.
    Abel, E. Jason
    Huang, Wei
    Eliceiri, Kevin W.
    [J]. BMC CANCER, 2019, 19 (1)